Effects of a high-fat meal on the relative oral bioavailability of piperaquine

被引:72
作者
Sim, IK
Davis, TME
Ilett, KF
机构
[1] Univ Western Australia, Sch Med & Pharmacol, Pharmacol Unit, Crawley, WA 6009, Australia
[2] Univ Western Australia, Sch Med & Pharmacol, Med Unit Fremantle, Crawley, WA 6009, Australia
[3] Western Australian Ctr Pathol & Med Res, Clin Pharmacol & Toxicol Lab, Nedlands, WA, Australia
关键词
D O I
10.1128/AAC.49.6.2407-2411.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Piperaquine (PQ) is an antimalarial drug whose high lipid solubility suggests that its absorption can be increased by a high-fat meal. We examined the pharmacokinetics of PQ phosphate (500 mg given orally) in the fasting state and after a high-fat meal in eight healthy Caucasian volunteers (randomized crossover). Plasma PQ concentration-time profiles were analyzed by using noncompartmental pharmacokinetic analysis. In the fed state, the geometric mean C-max increased by 213%, from 21.0 to 65.8 mu g/liter (P < 0.001). The time of C-max was not significantly different between the fasting and fed states. The geometric mean area under the concentration-time curve from zero onward (AUC(0-infinity)) increased by 98%, from 3,724 to 7,362 mu g h/liter (P = 0.006). The oral bioavailability of PQ relative to the fasting state was 121% greater after the high-fat meal (95% confidence interval, 26 to 216% increase; P = 0.020). The side effects, postural blood pressure changes, electrocardiographic corrected QT interval, serum glucose, and other biochemical and hematological indices were similar in the fasting and fed states over 28 days of follow-up.
引用
收藏
页码:2407 / 2411
页数:5
相关论文
共 25 条
[1]  
Chen L, 1989, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, V7, P81
[2]  
CHEN L, 1991, CHINESE MED J-PEKING, V104, P161
[3]  
CHEN L, 1982, CHINESE MED J-PEKING, V95, P281
[4]  
CHEN Q, 1979, PHARM IND, V8, P19
[5]   Food increases the bioavailability of mefloquine [J].
Crevoisier, C ;
Handschin, J ;
Barre, J ;
Roumenov, D ;
Kleinbloesem, C .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 53 (02) :135-139
[6]  
Davis TME, 2005, DRUGS, V65, P75, DOI 10.2165/00003495-200565010-00004
[7]   Antimalarial drugs and glucose metabolism [J].
Davis, TME .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (01) :1-7
[8]  
GIBALDI M, 1984, BIOPHARMACEUTICS CLI, P29
[9]  
Guo X B, 1993, Zhonghua Yi Xue Za Zhi, V73, P602
[10]  
GUO XB, 1989, ZHONG XI YI JIE HE Z, V9, P473